MASTER RESEARCH SERVICE AGREEMENTMaster Research Service Agreement • June 5th, 2024 • Onconetix, Inc. • Pharmaceutical preparations
This MASTER SERVICE AGREEMENT (this “Agreement”), effective as of October 1, 2022 (the “Effective Date”), is made by and between Immunovia, AB, a Swedish company having its principal place of business at Medicon Village, SE-223, 63, Lund Sweden (“Immunovia”) and Proteomedix AG., a Swiss Company having its principal place of business at Wagistrasse 23, CH-8952 Schlieren, Switzerland (“Proteomedix”). Immunovia and Proteomedix may be individually referred to as a “Party” or collectively as the “Parties” under this Agreement.
COLLABORATION AGREEMENTCollaboration Agreement • June 5th, 2024 • Onconetix, Inc. • Pharmaceutical preparations • London
Proteomedix AG, a diagnostic company having its registered office at Wagistrasse 23, CH-8952 Schlieren, Switzerland (hereinafter referred to as “PMX” or a “Party”)
AMENDMENT NO 1Collaboration Agreement • June 5th, 2024 • Onconetix, Inc. • Pharmaceutical preparations • London
Proteomedix AG, a diagnostic company having its registered office at Wagistrasse 23, CH-8952 Schlieren, Switzerland (hereinafter referred to as “PMX” or a “Party”)
